Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit.

  title={Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit.},
  author={Sherry Shu-Jung Hu},
  journal={The Chinese journal of physiology},
  volume={59 1},
  • S. Hu
  • Published 29 February 2016
  • Biology, Psychology
  • The Chinese journal of physiology
Rimonabant is well recognized as a cannabinoid CB₁ receptor antagonist/inverse agonist. Rimonabant not only antagonizes the effects induced by exogenous cannabinoids and endocannabinoids at CB₁ receptors, it also exerts several pharmacological and behavioral effects independent of CB₁ receptor inactivation. For example, rimonabant can function as a low-potency mixed agonist/antagonist of the transient receptor potential vanilloid receptor 1 (TRPV1). Hence, it is important to explain the… 

Figures from this paper



Vanilloid VR1 receptor is involved in rimonabant‐induced neuroprotection

The findings suggest that VR1 vanilloid receptors are involved in rimonabant's neuroprotection even if other mechanisms can contribute to this effect.

TRPV1 and Endocannabinoids: Emerging Molecular Signals that Modulate Mammalian Vision

The current evidence for localization and function of TRPV1 channels within the mammalian retina is evaluated and the potential interaction of this intriguing nociceptor with endogenous agonists and modulators is explored.

The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept

It is argued that TRPV1 antagonists alone or in conjunction with other analgesics will improve the quality of life of people with migraine, chronic intractable pain secondary to cancer, AIDS or diabetes, and emerging data indicate that TRPs could be useful in treating disorders other than pain, such as urinary urge incontinence, chronic cough and irritable bowel syndrome.

Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Most, but not all, CNS effects of Delta9-THC are mediated by the CB1 receptor, which accounts for the abuse potential of cannabis, while other effects such as analgesia suggest potential medicinal applications.

Cannabis and cannabinoids: pharmacology and rationale for clinical use.

  • R. Pertwee
  • Medicine, Biology
    Forschende Komplementarmedizin
  • 1999
It will be important to establish objectively and conclusively whether these agents have efficacy against selected symptoms that is of clinical significance and whether the benefits outweigh the risks, whether cannabis has therapeutic advantages over individual cannabinoids, and whether there is a need for additional drug treatments to manage any of the disorders against which cannabinoids are effective.

Circuit Specific Functions of Cannabinoid CB1 Receptor in the Balance of Investigatory Drive and Exploration

Results indicate that exploratory behaviour is accurately balanced in both, the social and non-social context, by the eCB system via CB1 receptor activation on cortical glutamatergic and GABAergic neurons.

The endocannabinoid system controls food intake via olfactory processes

The data indicate that cortical feedback projections to the MOB crucially regulate food intake via CB1 receptor signaling, linking the feeling of hunger to stronger odor processing.

An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors

The hypothesis, based on previous structure-activity relationship studies and the availability of biosynthetic precursors, that N-arachidonoyl-dopamine (NADA) is an endogenous “capsaicin-like” substance in mammalian nervous tissues is examined and found that NADA occurs in nervous tissues.